Stella Pharma (4888) · TargetRestated
Stable post-launch revenue generation and establishment of a business foundation
First written in FY2021. 1 of 2 entries say "Restated". Latest entry: FY2022.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Stable Monetization Through Approval and Sales of a Novel Anticancer DrugA theme 2 companies write about · 0 as a headwind · 2 as a tailwind
1 other company's latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「The Company’s immediate management objective is to generate stable post-launch revenue by raising awareness of BNCT as a new medical treatment and, in conjunction with this, establish a business foundation.」
The Company’s immediate objectives are stable post-launch revenue through greater awareness of BNCT and the establishment of a business foundation. - FY2021First statedAnnual report
「The Company’s immediate management objective is to generate stable post-launch revenue by raising awareness of BNCT as a new medical treatment and, in conjunction with this, establish a business foundation.」
As its immediate post-launch management objectives, the Company sets out stable revenue generation through greater awareness and the establishment of a business foundation.